PAINCHEK LTD — Capital/Financing Update 2020

Jun 4, 2020

==> picture [232 x 51] intentionally omitted <==

PainChek Limited ( ASX: PCK ) ABN 21 146 035 127 192020 Suite 401, 35 Lime Street, Sydney, NSW, 2000 Phone +61 8 9388 8290 info@painchek.com

PainChek receives 2[nd] federal government initiative payment of $1.25M

5[th] June 2020 : The Company is pleased to confirm it has now received the second $1.25 million payment from the Federal Government as part of the of the $5 million dementia grant initiative within Australian Residential Aged Care.

As communicated in the recent quarterly, this is a pre-payment for the second tranche of 25,000 PainChek licenses to be accessed by Aged Care Facilities for their residents living with dementia and cognitive impairment. The Company has now received a total of $3 million of the $5 million PainChek license fee payments from the Federal Government this financial year.

We thank the Federal Government and Department of Health for their support and for their agreement to extend the Dementia grant initiative timeline in order to deliver the 100,000 PainChek licenses to residents in Australian Aged Care by June 2021.

This ASX announcement has been approved for release by Philip Daffas, Managing Director.

For more information:	For more information:
Ian HobsonCompany Secretary, PainChekianhobson@bigpond.com+61 8 9388 8290	Philip DaffasCEO, PainChekphilip.daffas@painchek.com0406 537 235

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

PainChek® is a smart-phone based medical device using artificial intelligence to assess and score pain levels in real time and update medical records in the cloud. PainChek® records a short video of the person’s face and analyses the images that indicate pain and records them.

Next, the caregiver uses PainChek® to record their observations of other pain related behaviours that complete the assessment. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to monitor the effect of medication and treatment over time.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for Children who have not yet learnt to speak.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit www.painchek.com

==> picture [215 x 217] intentionally omitted <==

PainChek[®] artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain.

==> picture [215 x 216] intentionally omitted <==

PainChek[®] domains of pain assessment that calculates pain severity score.

==> picture [612 x 82] intentionally omitted <==